Bridgeway Capital Management’s Nautilus Biotechnolgy NAUT Stock Holding History

Bridgeway Capital Management’s Portfolio NAUT Stock Details NAUT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$337K	Buy	180,000 +50,000	+38%	+$132K	0.01%	953
2026 Q1	$504K	Hold	130,000	–	–	0.01%	827
2025 Q4	$254K	Buy	130,000 +5,000	+4%	+$8.2K	0.01%	973
2025 Q3	$106K	Hold	125,000	–	–	﹤0.01%	1105
2025 Q2	$90.6K	Buy	125,000 +75,000	+150%	+$56.3K	﹤0.01%	1086
2025 Q1	$43K	Buy	+50,000	New	+$74.3K	﹤0.01%	1127
2023 Q4	–	Sell	-38,800	Closed	-$123K	–	1401
2023 Q3	$123K	Hold	38,800	–	–	﹤0.01%	1189
2023 Q2	$150K	Hold	38,800	–	–	﹤0.01%	1192
2023 Q1	$107K	Buy	+38,800	New	+$81.4K	﹤0.01%	1223

Other funds holding NAUT

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACM

AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CFM

Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

Bridgeway Capital Management's NAUT Position: Q2 2026 in Review

Bridgeway Capital Management increased its Nautilus Biotechnolgy (NAUT) stake by 38% in Q2 2026, buying an estimated $132K and bringing the position to 180,000 shares worth $337K. The position accounts for 0.01% of the portfolio, ranked #953.

Bridgeway Capital Management first reported a position in NAUT in Q1 2023 and has held it in 9 quarters since. The position peaked at $504K in Q1 2026. 93 funds tracked by Wall St. Rank hold NAUT as of Q2 2026.

Bridgeway Capital Management held 180,000 shares of Nautilus Biotechnolgy worth $337K as of Q2 2026.
Bridgeway Capital Management bought 50,000 Nautilus Biotechnolgy shares in Q2 2026, an estimated $132K.
Nautilus Biotechnolgy made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #953 holding.
Bridgeway Capital Management first reported a position in Nautilus Biotechnolgy in Q1 2023 and has held it in 9 quarters since.
Bridgeway Capital Management's Nautilus Biotechnolgy position peaked at $504K in Q1 2026.
93 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.